A2 to O Lung Transplants

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Oct 11, 2022

Keywords

ClinConnect Summary

This clinical trial, called "A2 to O Lung Transplants," is exploring the possibility of safely transplanting lungs from donors with blood type A2 into recipients with blood type O. This is important because patients with type O blood often face longer waiting times for lung transplants and may have a higher risk of not surviving while waiting. The study aims to see if these types of transplants can be done safely and effectively, which would help more people receive the lungs they need more quickly.

To participate in this trial, you must be a first-time lung transplant candidate with blood type O, have low levels of certain antibodies in your blood, and agree to be part of the study. Unfortunately, those who have had a previous lung transplant, are receiving multiple organ transplants, or have a positive crossmatch test (indicating potential rejection) cannot join. If eligible, you can expect to undergo careful monitoring and support throughout the transplant process. This study is unique as it is the first of its kind globally, aiming to improve outcomes for lung transplant candidates with blood type O.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • first lung transplant
• • blood group O recipient
• • low pre-operative anti-A antibody titers
• • consent to study participation
• Exclusion Criteria:
• • re-transplant
• • multiorgan transplant
• • positive virtual crossmatch at time of transplant